Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases.
Recombinant factor VIIa (rFVIIa) was envisioned for the treatment of bleeding in hemophilia patients with inhibitors. In response to tissue factor expressed upon vessel wall injury, rFVIIa amplifies the thrombin burst primarily on membrane surfaces, including activated platelets. Because it is functional at a key point in the clotting cascade, rFVIIa shows promise as a therapeutic option for various bleeding situations. The prothrombin time (PT) is often used as a surrogate to monitor rFVIIa therapy. Using laboratory and clinical measures of outcome, the use of rVIIa as a therapeutic option in treating several different pediatric coagulopathic conditions is described.
Mathew
Prasad
P
University of New Mexico, Department of Pediatrics, Pediatric Hematology/Oncology, Albuquerque, New Mexico 87131-5311, USA. pmathew@salud.unm.edu
Winter
Stuart S
SS
Frost
Jami D
JD
Hanrahan
Jeffrey
J
Schwartz
Marcia
M
Jones
Jane E
JE
D000293:Adolescent; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D002675:Child, Preschool; D005167:Factor VII / Q000008:administration & dosage / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa